1. Home
  2. APLT vs AMAL Comparison

APLT vs AMAL Comparison

Compare APLT & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • AMAL
  • Stock Information
  • Founded
  • APLT 2016
  • AMAL 1923
  • Country
  • APLT United States
  • AMAL United States
  • Employees
  • APLT N/A
  • AMAL N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • AMAL Commercial Banks
  • Sector
  • APLT Health Care
  • AMAL Finance
  • Exchange
  • APLT Nasdaq
  • AMAL Nasdaq
  • Market Cap
  • APLT 971.6M
  • AMAL 1.0B
  • IPO Year
  • APLT 2019
  • AMAL 2018
  • Fundamental
  • Price
  • APLT $9.09
  • AMAL $32.87
  • Analyst Decision
  • APLT Strong Buy
  • AMAL Buy
  • Analyst Count
  • APLT 5
  • AMAL 3
  • Target Price
  • APLT $12.50
  • AMAL $32.17
  • AVG Volume (30 Days)
  • APLT 1.5M
  • AMAL 162.3K
  • Earning Date
  • APLT 11-15-2024
  • AMAL 10-24-2024
  • Dividend Yield
  • APLT N/A
  • AMAL 1.46%
  • EPS Growth
  • APLT N/A
  • AMAL 16.43
  • EPS
  • APLT N/A
  • AMAL 3.39
  • Revenue
  • APLT N/A
  • AMAL $303,073,000.00
  • Revenue This Year
  • APLT N/A
  • AMAL N/A
  • Revenue Next Year
  • APLT $3,349.45
  • AMAL $5.34
  • P/E Ratio
  • APLT N/A
  • AMAL $9.68
  • Revenue Growth
  • APLT N/A
  • AMAL 12.52
  • 52 Week Low
  • APLT $1.79
  • AMAL $18.56
  • 52 Week High
  • APLT $9.39
  • AMAL $35.30
  • Technical
  • Relative Strength Index (RSI)
  • APLT 61.27
  • AMAL 53.38
  • Support Level
  • APLT $8.38
  • AMAL $33.10
  • Resistance Level
  • APLT $9.29
  • AMAL $34.71
  • Average True Range (ATR)
  • APLT 0.55
  • AMAL 0.85
  • MACD
  • APLT -0.06
  • AMAL -0.14
  • Stochastic Oscillator
  • APLT 76.93
  • AMAL 26.92

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

Share on Social Networks: